



Agilis Biotherapeutics Co-Sponsors and Presents at NeuroAdvance Boston Conference

Forum Brings Together Experts in Field of Neurological and Central Nervous System Disorders

Cambridge, MA, October 16, 2015 -- Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Agilis co-sponsored the Boston Biotech Conferences (BBC)'s NeuroAdvance Conference at Harvard Medical School in Boston, MA. Mark Pykett, President and CEO of Agilis, moderated the session "Gene Therapy Approaches to CNS Disorders", bringing together leaders from academia and industry to discuss emerging therapeutic strategies using gene replacement to treat intractable diseases of the CNS. The session covered a range topics in CNS gene therapy, including recent successes in clinical trials, advances in the regulatory environment for gene therapy, progress in manufacturing for gene therapy products, and optimization of gene constructs and delivery vectors. Dr. Pykett noted Agilis' recent progress in its engineering and testing activities for the Company's core gene therapy programs in Friedreich's Ataxia and Angelman Syndrome.

"The conference highlights the remarkable progress being realized in treating disorders of the central nervous system," stated Dr. Pykett. "We are pleased that Agilis was able to co-sponsor this event. The session on gene therapy approaches to CNS disorders demonstrated the growing capabilities of this novel intervention strategy in bringing new treatment solutions to patients across a range of CNS disorders. Agilis' progress in advancing its gene therapy programs for Friedreich's Ataxia and Angelman Syndrome to first-in-man studies positions the Company at the forefront of this exciting field, which holds great promise for a spectrum of serious CNS disorders where few treatment options exist."

BBC's NeuroAdvance Boston focuses on the latest developments and opportunities in neuroscience for creating new therapies. The conference brings together luminaries in neuroscience research and

development, as well as executives of the next generation of the leading neuro companies, in discussion on the most relevant issues facing neuroscience and biotechnology today. BBC focuses on building a vibrant community of biopharma leaders to help to drive innovation in biotech by convening leaders across industry and academia. BBC conferences are thought-leader forums for senior biopharma executives co-hosted by healthcare industry leaders that facilitate information-sharing, networking, and corporate development within the biopharma community.

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's Ataxia, Angelman Syndrome and Fragile X Syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's Ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 people living with Angelman Syndrome in the US. Fragile X Syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and

uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809